Regorafenib induces DNA damage and enhances PARP inhibitor efficacy in pancreatic ductal carcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Regorafenib induces DNA damage and enhances PARP inhibitor efficacy in pancreatic ductal carcinoma ; volume:24 ; number:1 ; day:20 ; month:12 ; year:2024 ; pages:1-12 ; date:12.2024
BMC cancer ; 24, Heft 1 (20.12.2024), 1-12, 12.2024
- Creator
-
Pham, Thao D.
Becker, Jeffrey H.
Metropulos, Anastasia E.
Mubin, Nida
Spaulding, Christina
Bentrem, David J.
Munshi, Hidayatullah G.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-024-13334-y
- URN
-
urn:nbn:de:101:1-2503012106489.888590398523
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Pham, Thao D.
- Becker, Jeffrey H.
- Metropulos, Anastasia E.
- Mubin, Nida
- Spaulding, Christina
- Bentrem, David J.
- Munshi, Hidayatullah G.
- SpringerLink (Online service)
Other Objects (12)
Co-targeting WIP1 and PARP induces synthetic lethality in hepatocellular carcinoma
PARP inhibitors
Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
Regorafenib : kolorektales Karzinom: Behandlungsoption nach Standardtherapie
Regorafenib: Nutzenbewertung gemäß § 35a SGB V
Regorafenib: Addendum zum Auftrag A15-43
Addendum zum Auftrag A13-37 (Regorafenib)
Regorafenib - Nutzenbewertung gemäß § 35a SGB V
PD ‐L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy
ATM depletion induces proteasomal degradation of FANCD2 and sensitizes neuroblastoma cells to PARP inhibitors
Aberrant APOBEC3C expression induces characteristic genomic instability in pancreatic ductal adenocarcinoma
Co-targeting WIP1 and PARP induces synthetic lethality in hepatocellular carcinoma
PARP inhibitors
Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
Regorafenib : kolorektales Karzinom: Behandlungsoption nach Standardtherapie
Regorafenib: Nutzenbewertung gemäß § 35a SGB V
Regorafenib: Addendum zum Auftrag A15-43
Addendum zum Auftrag A13-37 (Regorafenib)
Regorafenib - Nutzenbewertung gemäß § 35a SGB V
PD ‐L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy
ATM depletion induces proteasomal degradation of FANCD2 and sensitizes neuroblastoma cells to PARP inhibitors
Aberrant APOBEC3C expression induces characteristic genomic instability in pancreatic ductal adenocarcinoma
Co-targeting WIP1 and PARP induces synthetic lethality in hepatocellular carcinoma
PARP inhibitors
Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
Regorafenib : kolorektales Karzinom: Behandlungsoption nach Standardtherapie
Regorafenib: Nutzenbewertung gemäß § 35a SGB V
Regorafenib: Addendum zum Auftrag A15-43
Addendum zum Auftrag A13-37 (Regorafenib)
Regorafenib - Nutzenbewertung gemäß § 35a SGB V
PD ‐L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy
ATM depletion induces proteasomal degradation of FANCD2 and sensitizes neuroblastoma cells to PARP inhibitors